Skip to content
Shoreline Biosciences
  • Home
  • About Us
    • Leadership Team
    • Directors
    • Scientific Advisory Board
    • Investors & Partners
  • Our Science
    • Platform
    • iNK
    • iMACs
  • News
  • Join Us!
  • Contact
  • Home
  • About Us
    • Leadership Team
    • Directors
    • Scientific Advisory Board
    • Investors & Partners
  • Our Science
    • Platform
    • iNK
    • iMACs
  • News
  • Join Us!
  • Contact
Shoreline Biosciences
  • Home
  • About Us
    • Leadership Team
    • Directors
    • Scientific Advisory Board
    • Investors & Partners
  • Our Science
    • Platform
    • iNK
    • iMACs
  • News
  • Join Us!
  • Contact
  • Home
  • About Us
    • Leadership Team
    • Directors
    • Scientific Advisory Board
    • Investors & Partners
  • Our Science
    • Platform
    • iNK
    • iMACs
  • News
  • Join Us!
  • Contact

    Featured News

    Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

    January 19, 2023
    Read More

    Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer

    October 24, 2022
    Read More

    Press Releases

    Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

    January 19, 2023
    READ MORE

    Shoreline Biosciences Announces Oral Presentation on Novel Manufacturing Method of Ink Cells at The 64th American Society of Hematology (ASH) 2022 Meeting

    December 5, 2022
    READ MORE

    Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer

    October 24, 2022
    READ MORE

    Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022)

    May 10, 2022
    READ MORE

    Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells

    April 12, 2022
    READ MORE

    Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022

    March 28, 2022
    READ MORE
    LOAD MORE

    Media

    A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs

    July 9, 2022
    READ MORE

    BioWorld Insider Podcast: One-on-one with Medical Innovators

    February 7, 2022
    READ MORE

    BioWorld Insider Podcast: One-on-one with Medical Innovators

    December 10, 2021
    READ MORE

    Harnessing the body’s natural killers to target cancer

    December 5, 2021
    READ MORE

    Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing

    November 8, 2021
    READ MORE

    California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award

    November 4, 2021
    READ MORE
    LOAD MORE
    Shoreline Biosciences
    • 10220 Sorrento Valley Road
      San Diego, CA 92121
    • Email Shoreline
    Linkedin

    Join Our Newsletter

    ©2022 Shoreline Biosciences. All Rights Reserved.